AOD-9604

AOD-9604 is a synthetic peptide fragment corresponding to the C-terminal region of human growth hormone (hGH 176–191). It was developed to retain lipolytic (“fat loss”) signaling while avoiding the growth-promoting and diabetogenic effects associated with full-length growth hormone. Research has explored its anti-obesity potential and possible cartilage-related effects.

— 2 mg Vial —

Reconstitute: Add 3.0 mL bacteriostatic water → ~0.667 mg/mL (667 mcg/mL) concentration.
Typical daily range: 300–500 mcg once daily (gradual titration).
Easy measuring: At 0.667 mg/mL, 1 unit = 0.01 mL ≈ 6.67 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.

Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Goal: Support reduction of fat mass and enhance fat oxidation over time.

Frequency: Inject once daily subcutaneously (typically in the morning on an empty stomach). Rotate injection sites to minimize local irritation.

— 5 mg Vial —

Reconstitute: Add 3.0 mL bacteriostatic water → ~1.667 mg/mL (1667 mcg/mL) concentration.
Typical daily range: 300–500 mcg once daily (gradual titration).
Easy measuring: At 1.667 mg/mL, 1 unit = 0.01 mL ≈ 16.67 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.

Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Goal: Support reduction of fat mass and enhance fat oxidation over time.

Frequency: Inject once daily subcutaneously (typically in the morning on an empty stomach). Rotate injection sites to minimize local irritation.

• Investigated for effects on body fat reduction in overweight/obesity studies.
• May promote lipolysis and inhibit lipogenesis in experimental models.
• Explored for cartilage-related signaling in some preclinical contexts.
• Often described as having minimal impact on blood glucose/IGF-1 compared with GH (study-dependent).

• Injection site irritation (SubQ).
• Headache (reported in some studies).
• Nausea or fatigue (occasionally).
• Allergic reactions possible.

• Pregnancy/breastfeeding (avoid).
• Active malignancy or uncontrolled endocrine disease without clinician oversight.
• Known hypersensitivity to peptide or excipients.

• Often discussed with GLP-1 therapies or lifestyle fat-loss plans; avoid stacking multiple appetite/weight agents without clinician oversight.
• If pairing with training, prioritize protein intake and resistance training to preserve lean mass.

1. Ng FM et al. J Endocrinol. 2005. PMID: 15677463
2. Heffernan M et al. Int J Obes (Lond). 2004. PMID: 15126546
3. Francois M et al. Obes Res. 2005. PMID: 16204365
4. Harris M et al. Clin Endocrinol (Oxf). 2003. PMID: 14584155
5. Vickers MH et al. Endocrinology. 2003. PMID: 12865320
6. Bach LA. Growth Horm IGF Res. 2006. PMID: 17135376